Clinical Trial Update: An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 open-label dose-escalation study evaluating safety, pharmacokinetics, pharmacodynamics, and early clinical activity of GSK3326595 in participants with s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• GSK3326595

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2025-03-10